Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.54 |
| ▸ | FYN | P06241 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254085 | 0.94 | SRC (0.61) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3228357 | 0.89 | SRC (0.54) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3222755 | 0.86 | SRC (0.56) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3234657 | 0.86 | SRC (0.62) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3229483 | 0.82 | SRC (0.72) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3222349 | 0.82 | SRC (0.72) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3212451 | 0.82 | SRC (0.64) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3225938 | 0.81 | SRC (0.59) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3224739 | 0.80 | SRC (0.63) | SRCFYNEGFRMAP2K1 | |
| SCHEMBL3228029 | 0.80 | SRC (0.59) | SRCFYNEGFRMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010030835-A2 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069340-A1 | PHARMACEUTICAL COMPOSITIONS OF AN SRC KINASE INHIBITOR AND AN AROMATASE INHIBITOR | CYP19A1, SRC, CYP17A1 | SRC 2/4885FYN 13/4885EGFR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.